pRDB-054_4x_crAGAT
(Plasmid
#261345)
-
PurposeLentiviral vector encoding enAsCas12a and a four-guide casette targeting human AGAT under puro selection
-
Depositing Lab
-
Depositing OrganizationUniversity of Texas Southwestern Medical Center
Located in the United States of America -
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 261345 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
Backbone
-
Vector backbonepRDB-054
-
Backbone manufacturerJohn Doench, Addgene plasmid #216096
-
Vector typeMammalian Expression, Lentiviral, CRISPR
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameAGAT
-
gRNA/shRNA sequenceGTCTGACAGGTTTATACAGTGCA, GGAGCTGTTGTCCACTTGGCGCC, ATAATTGACCTGTACGCTCGGTA, TGCTCTGCCCACTATCACTTCC
-
SpeciesH. sapiens (human)
-
Insert Size (bp)3918
-
Entrez GeneGATM (a.k.a. AGAT, AT, CCDS3, FRTS, FRTS1, RFS)
- Promoter EF-1alpha
-
Tag
/ Fusion Protein
- Nucleoplasmin NLS, 3xHA (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BsmBI (not destroyed)
- 3′ cloning site BsmBI (not destroyed)
Resource Information
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please visit https://doi.org/10.1101/2025.09.15.676412 for bioRxiv preprint.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pRDB-054_4x_crAGAT was a gift from Samuel McBrayer (Addgene plasmid # 261345 ; http://n2t.net/addgene:261345 ; RRID:Addgene_261345) -
For your References section:
Gliomas phenocopy an inborn error of metabolism to drive neuronal activity and tumor growth. Abdullah KG, Miki K, Edgar CK, Wu SA, Xiao Y, Huang YT, Drexler R, Krishna S, Puliyappadamba VT, Tay LWR, Yuan F, Savani MR, Ghoche MT, Kotermanski SE, Traylor JI, Guo L, Gunn K, Hicks WH, Shi DD, Yalcin B, Kilian K, Tang M, Moyer M, Levitt MM, El-Shami M, Oken S, Manoj N, Gattie LC, Smith BC, Kaphle P, Shipman T, West RE 3rd, Liang C, Eshac Y, Chia TY, Patel TR, Hatanpaa KJ, Raj P, Miska JM, Ramirez DMO, Ma S, Nolin TD, Lega BC, Zinn PO, Kuhn BJ, Clark NM, Williams C, Mani DR, Gillette MA, Calzado MA, Xu L, Zacharias LG, Cai F, Ksendzovsky A, Mathews TP, Losman JA, Levi B, Barron T, Gibson JR, Richardson TE, Khan OH, Agnihotri S, Hervey-Jumper SL, Chamberland S, Monje M, Huber KM, DeBerardinis RJ, McBrayer SK. Cell. 2026 Sep 15:S0092-8674(26)01010-X. doi: 10.1016/j.cell.2026.08.037. 10.1016/j.cell.2026.08.037 PubMed 42743926